CagriSema 0.5 mg: Dosing Guide & What to Expect

When your prescriber recommends CagriSema 0.5 mg, you're progressing through the standard dose escalation protocol. This guide covers the clinical evidence, typical side effect patterns, and titration guidance specific to this dose.

What Is CagriSema 0.5 mg?

CagriSema (Cagrilintide + Semaglutide (combination)) is a GLP-1 receptor agonist + Amylin analog (cagrilintide) administered by weekly subcutaneous injection. The 0.5 mg dose is the week 8 titration dose in the standard titration protocol, designed to progressively increase receptor engagement and clinical efficacy.

Clinical trial data from REDEFINE-1 demonstrates a mean weight loss of approximately 22.7% at the maximum dose (2.4 mg) in trial-eligible participants. Results at intermediate doses like 0.5 mg are typically lower.

Titration Schedule for CagriSema

Patients typically remain at 0.5 mg for 4 weeks before escalating to CagriSema 1.0 mg, assuming the dose is well tolerated.

Side Effects at 0.5 mg

The most commonly reported side effects of CagriSema include GI-related symptoms that tend to be most pronounced during dose escalation. At 0.5 mg (a higher titration step), some patients experience more pronounced GI symptoms than at lower doses.

• •Nausea
• •Vomiting
• •Diarrhea
• •Constipation
• •Injection Site Reaction
• •Fatigue
• •Headache

Most side effects are transient and improve within 2–4 weeks at a stable dose. GI symptoms (nausea, diarrhea, constipation) are the most common reasons for dose reduction or discontinuation.

When to Call Your Doctor

• Persistent vomiting preventing adequate hydration
• Severe abdominal pain that does not resolve
• Signs of pancreatitis (severe upper abdominal pain radiating to back)
• Any signs of allergic reaction
• Heart rate increase of >20 bpm at rest that persists

When to Escalate from 0.5 mg

Standard protocol calls for 4 weeks at each dose level before escalation, provided the dose is well tolerated. If side effects are significant, your prescriber may recommend staying at 0.5 mg for an additional 4 weeks (an 8-week interval) before moving up.

Do not escalate doses without prescriber guidance. Self-directed dose escalation increases the risk of adverse events.

Contraindications & Safety

This medication is investigational and not approved for clinical use outside of clinical trials. Key contraindications include:

• Investigational combination — contraindications not yet fully established
• Similar profile to semaglutide expected

Pregnancy: Investigational — not established. Discuss with your prescriber if pregnancy is a possibility.